Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies

Michael B. Atkins, Michael Robertson, Michael Gordon, Michael T. Lotze, Michelle DeCoste, Jon S. DuBois, Jerome Ritz, Alan B. Sandler, Howard D. Edington, Pamela D. Garzone, James W. Mier, Christine M. Canning, Linda Battiato, Hideaki Tahara, Matthew L. Sherman

Research output: Contribution to journalArticle

410 Citations (Scopus)

Abstract

A Phase I dose escalation trial of i.v. administered recombinant human interleukin 12 (rhIL-12) was performed to determine its toxicity, maximum tolerated dose (MTD), pharmacokinetics, and biological and potential antineoplastic effects. Cohorts of four to six patients with advanced cancer, Karnofsky performance ≤70%, and normal organ function received escalating doses (3-1000 ng/kg/day) of rhIL-12 (Genetics Institute, Inc.) by bolus i.v. injection once as an inpatient and then, after a 2-week rest period, once daily for five days every 3 weeks as an outpatient. Therapy was withheld for grade 3 toxicity (grade 4 hyperbilirubinemia or neutropenia) and dose escalation was halted if three of six patients experienced a dose-limiting toxicity (DLT). After establishment of the MTD, eight more patients were enrolled to further assess the safety, pharmacokinetics, and immunobiology of this dose. Forty patients were enrolled, including 20 with renal cancer, 12 with melanoma, and 5 with colon cancer; 25 patients had received prior systemic therapy. Common toxicities included fever/chills, fatigue, nausea, vomiting, and headache. Fever was first observed at the 3 ng/kg dose level, typically occurred 8-12 h after rhIL-12 administration, and was incompletely suppressed with nonsteroidal anti-inflammatory drugs. Routine laboratory changes included anemia, neutropenia, lymphopenia, hyperglycemia, thrombocytopenia, and hypoalbuminemia. DLTs included oral stomatitis and liver function test abnormalities, predominantly elevated transaminases, which occurred in three of four patients at the 1000 ng/kg dose level. The 500 ng/kg dose level was determined to be the MTD. This dose, administered by this schedule, was associated with asymptomatic hepatic function test abnormalities in three patients and an onstudy death due to Clostridia perfringens septicemia but was otherwise well tolerated by the 14 patients treated in the dose escalation and safety phases. The T( 1/4 ) elimination of rhIL-12 was calculated to be 5.3-9.6 h. Biological effects included dose-dependent increases in circulating IFN-γ, which exhibited attenuation with subsequent cycles. Serum neopterin rose in a reproducible fashion regardless of dose or cycle. Tumor necrosis factor α was not detected by ELISA. One of 40 patients developed a low titer antibody to rhIL-12. Lymphopenia was observed at all dose levels, with recovery occurring within several days of completing treatment without rebound lymphocytosis. There was one partial response (renal cell cancer) and one transient complete response (melanoma), both in previously untreated patients. Four additional patients received all proposed treatment without disease progression. rhIL-12 administered according to this schedule is biologically and clinically active at doses tolerable by most patients in an outpatient setting. Nonetheless, additional Phase I studies examining different schedules and the mechanism of the specific DLTs are indicated before proceeding to Phase II testing.

Original languageEnglish (US)
Pages (from-to)409-417
Number of pages9
JournalClinical Cancer Research
Volume3
Issue number3
StatePublished - 1997
Externally publishedYes

Fingerprint

Interleukin-12
Neoplasms
Maximum Tolerated Dose
Appointments and Schedules
Lymphopenia
Neutropenia
Melanoma
Fever
Outpatients
Pharmacokinetics
Neopterin
Safety
Lymphocytosis
Hypoalbuminemia
Chills
Stomatitis
Clostridium perfringens
Hyperbilirubinemia
Kidney Neoplasms
Liver Function Tests

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Atkins, M. B., Robertson, M., Gordon, M., Lotze, M. T., DeCoste, M., DuBois, J. S., ... Sherman, M. L. (1997). Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clinical Cancer Research, 3(3), 409-417.

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. / Atkins, Michael B.; Robertson, Michael; Gordon, Michael; Lotze, Michael T.; DeCoste, Michelle; DuBois, Jon S.; Ritz, Jerome; Sandler, Alan B.; Edington, Howard D.; Garzone, Pamela D.; Mier, James W.; Canning, Christine M.; Battiato, Linda; Tahara, Hideaki; Sherman, Matthew L.

In: Clinical Cancer Research, Vol. 3, No. 3, 1997, p. 409-417.

Research output: Contribution to journalArticle

Atkins, MB, Robertson, M, Gordon, M, Lotze, MT, DeCoste, M, DuBois, JS, Ritz, J, Sandler, AB, Edington, HD, Garzone, PD, Mier, JW, Canning, CM, Battiato, L, Tahara, H & Sherman, ML 1997, 'Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies', Clinical Cancer Research, vol. 3, no. 3, pp. 409-417.
Atkins, Michael B. ; Robertson, Michael ; Gordon, Michael ; Lotze, Michael T. ; DeCoste, Michelle ; DuBois, Jon S. ; Ritz, Jerome ; Sandler, Alan B. ; Edington, Howard D. ; Garzone, Pamela D. ; Mier, James W. ; Canning, Christine M. ; Battiato, Linda ; Tahara, Hideaki ; Sherman, Matthew L. / Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 3. pp. 409-417.
@article{1bb634c3b28e4967a33aac9c6becc25a,
title = "Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies",
abstract = "A Phase I dose escalation trial of i.v. administered recombinant human interleukin 12 (rhIL-12) was performed to determine its toxicity, maximum tolerated dose (MTD), pharmacokinetics, and biological and potential antineoplastic effects. Cohorts of four to six patients with advanced cancer, Karnofsky performance ≤70{\%}, and normal organ function received escalating doses (3-1000 ng/kg/day) of rhIL-12 (Genetics Institute, Inc.) by bolus i.v. injection once as an inpatient and then, after a 2-week rest period, once daily for five days every 3 weeks as an outpatient. Therapy was withheld for grade 3 toxicity (grade 4 hyperbilirubinemia or neutropenia) and dose escalation was halted if three of six patients experienced a dose-limiting toxicity (DLT). After establishment of the MTD, eight more patients were enrolled to further assess the safety, pharmacokinetics, and immunobiology of this dose. Forty patients were enrolled, including 20 with renal cancer, 12 with melanoma, and 5 with colon cancer; 25 patients had received prior systemic therapy. Common toxicities included fever/chills, fatigue, nausea, vomiting, and headache. Fever was first observed at the 3 ng/kg dose level, typically occurred 8-12 h after rhIL-12 administration, and was incompletely suppressed with nonsteroidal anti-inflammatory drugs. Routine laboratory changes included anemia, neutropenia, lymphopenia, hyperglycemia, thrombocytopenia, and hypoalbuminemia. DLTs included oral stomatitis and liver function test abnormalities, predominantly elevated transaminases, which occurred in three of four patients at the 1000 ng/kg dose level. The 500 ng/kg dose level was determined to be the MTD. This dose, administered by this schedule, was associated with asymptomatic hepatic function test abnormalities in three patients and an onstudy death due to Clostridia perfringens septicemia but was otherwise well tolerated by the 14 patients treated in the dose escalation and safety phases. The T( 1/4 ) elimination of rhIL-12 was calculated to be 5.3-9.6 h. Biological effects included dose-dependent increases in circulating IFN-γ, which exhibited attenuation with subsequent cycles. Serum neopterin rose in a reproducible fashion regardless of dose or cycle. Tumor necrosis factor α was not detected by ELISA. One of 40 patients developed a low titer antibody to rhIL-12. Lymphopenia was observed at all dose levels, with recovery occurring within several days of completing treatment without rebound lymphocytosis. There was one partial response (renal cell cancer) and one transient complete response (melanoma), both in previously untreated patients. Four additional patients received all proposed treatment without disease progression. rhIL-12 administered according to this schedule is biologically and clinically active at doses tolerable by most patients in an outpatient setting. Nonetheless, additional Phase I studies examining different schedules and the mechanism of the specific DLTs are indicated before proceeding to Phase II testing.",
author = "Atkins, {Michael B.} and Michael Robertson and Michael Gordon and Lotze, {Michael T.} and Michelle DeCoste and DuBois, {Jon S.} and Jerome Ritz and Sandler, {Alan B.} and Edington, {Howard D.} and Garzone, {Pamela D.} and Mier, {James W.} and Canning, {Christine M.} and Linda Battiato and Hideaki Tahara and Sherman, {Matthew L.}",
year = "1997",
language = "English (US)",
volume = "3",
pages = "409--417",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies

AU - Atkins, Michael B.

AU - Robertson, Michael

AU - Gordon, Michael

AU - Lotze, Michael T.

AU - DeCoste, Michelle

AU - DuBois, Jon S.

AU - Ritz, Jerome

AU - Sandler, Alan B.

AU - Edington, Howard D.

AU - Garzone, Pamela D.

AU - Mier, James W.

AU - Canning, Christine M.

AU - Battiato, Linda

AU - Tahara, Hideaki

AU - Sherman, Matthew L.

PY - 1997

Y1 - 1997

N2 - A Phase I dose escalation trial of i.v. administered recombinant human interleukin 12 (rhIL-12) was performed to determine its toxicity, maximum tolerated dose (MTD), pharmacokinetics, and biological and potential antineoplastic effects. Cohorts of four to six patients with advanced cancer, Karnofsky performance ≤70%, and normal organ function received escalating doses (3-1000 ng/kg/day) of rhIL-12 (Genetics Institute, Inc.) by bolus i.v. injection once as an inpatient and then, after a 2-week rest period, once daily for five days every 3 weeks as an outpatient. Therapy was withheld for grade 3 toxicity (grade 4 hyperbilirubinemia or neutropenia) and dose escalation was halted if three of six patients experienced a dose-limiting toxicity (DLT). After establishment of the MTD, eight more patients were enrolled to further assess the safety, pharmacokinetics, and immunobiology of this dose. Forty patients were enrolled, including 20 with renal cancer, 12 with melanoma, and 5 with colon cancer; 25 patients had received prior systemic therapy. Common toxicities included fever/chills, fatigue, nausea, vomiting, and headache. Fever was first observed at the 3 ng/kg dose level, typically occurred 8-12 h after rhIL-12 administration, and was incompletely suppressed with nonsteroidal anti-inflammatory drugs. Routine laboratory changes included anemia, neutropenia, lymphopenia, hyperglycemia, thrombocytopenia, and hypoalbuminemia. DLTs included oral stomatitis and liver function test abnormalities, predominantly elevated transaminases, which occurred in three of four patients at the 1000 ng/kg dose level. The 500 ng/kg dose level was determined to be the MTD. This dose, administered by this schedule, was associated with asymptomatic hepatic function test abnormalities in three patients and an onstudy death due to Clostridia perfringens septicemia but was otherwise well tolerated by the 14 patients treated in the dose escalation and safety phases. The T( 1/4 ) elimination of rhIL-12 was calculated to be 5.3-9.6 h. Biological effects included dose-dependent increases in circulating IFN-γ, which exhibited attenuation with subsequent cycles. Serum neopterin rose in a reproducible fashion regardless of dose or cycle. Tumor necrosis factor α was not detected by ELISA. One of 40 patients developed a low titer antibody to rhIL-12. Lymphopenia was observed at all dose levels, with recovery occurring within several days of completing treatment without rebound lymphocytosis. There was one partial response (renal cell cancer) and one transient complete response (melanoma), both in previously untreated patients. Four additional patients received all proposed treatment without disease progression. rhIL-12 administered according to this schedule is biologically and clinically active at doses tolerable by most patients in an outpatient setting. Nonetheless, additional Phase I studies examining different schedules and the mechanism of the specific DLTs are indicated before proceeding to Phase II testing.

AB - A Phase I dose escalation trial of i.v. administered recombinant human interleukin 12 (rhIL-12) was performed to determine its toxicity, maximum tolerated dose (MTD), pharmacokinetics, and biological and potential antineoplastic effects. Cohorts of four to six patients with advanced cancer, Karnofsky performance ≤70%, and normal organ function received escalating doses (3-1000 ng/kg/day) of rhIL-12 (Genetics Institute, Inc.) by bolus i.v. injection once as an inpatient and then, after a 2-week rest period, once daily for five days every 3 weeks as an outpatient. Therapy was withheld for grade 3 toxicity (grade 4 hyperbilirubinemia or neutropenia) and dose escalation was halted if three of six patients experienced a dose-limiting toxicity (DLT). After establishment of the MTD, eight more patients were enrolled to further assess the safety, pharmacokinetics, and immunobiology of this dose. Forty patients were enrolled, including 20 with renal cancer, 12 with melanoma, and 5 with colon cancer; 25 patients had received prior systemic therapy. Common toxicities included fever/chills, fatigue, nausea, vomiting, and headache. Fever was first observed at the 3 ng/kg dose level, typically occurred 8-12 h after rhIL-12 administration, and was incompletely suppressed with nonsteroidal anti-inflammatory drugs. Routine laboratory changes included anemia, neutropenia, lymphopenia, hyperglycemia, thrombocytopenia, and hypoalbuminemia. DLTs included oral stomatitis and liver function test abnormalities, predominantly elevated transaminases, which occurred in three of four patients at the 1000 ng/kg dose level. The 500 ng/kg dose level was determined to be the MTD. This dose, administered by this schedule, was associated with asymptomatic hepatic function test abnormalities in three patients and an onstudy death due to Clostridia perfringens septicemia but was otherwise well tolerated by the 14 patients treated in the dose escalation and safety phases. The T( 1/4 ) elimination of rhIL-12 was calculated to be 5.3-9.6 h. Biological effects included dose-dependent increases in circulating IFN-γ, which exhibited attenuation with subsequent cycles. Serum neopterin rose in a reproducible fashion regardless of dose or cycle. Tumor necrosis factor α was not detected by ELISA. One of 40 patients developed a low titer antibody to rhIL-12. Lymphopenia was observed at all dose levels, with recovery occurring within several days of completing treatment without rebound lymphocytosis. There was one partial response (renal cell cancer) and one transient complete response (melanoma), both in previously untreated patients. Four additional patients received all proposed treatment without disease progression. rhIL-12 administered according to this schedule is biologically and clinically active at doses tolerable by most patients in an outpatient setting. Nonetheless, additional Phase I studies examining different schedules and the mechanism of the specific DLTs are indicated before proceeding to Phase II testing.

UR - http://www.scopus.com/inward/record.url?scp=0030887047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030887047&partnerID=8YFLogxK

M3 - Article

C2 - 9815699

AN - SCOPUS:0030887047

VL - 3

SP - 409

EP - 417

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -